Literature DB >> 14570746

Angiogenesis in endocrine tumors.

Helen E Turner1, Adrian L Harris, Shlomo Melmed, John A H Wass.   

Abstract

Angiogenesis is the process of new blood vessel development from preexisting vasculature. Although vascular endothelium is usually quiescent in the adult, active angiogenesis has been shown to be an important process for new vessel formation, tumor growth, progression, and spread. The angiogenic phenotype depends on the balance of proangiogenic growth factors such as vascular endothelial growth factor (VEGF) and inhibitors, as well as interactions with the extracellular matrix, allowing for endothelial migration. Endocrine glands are typically vascular organs, and their blood supply is essential for normal function and tight control of hormone feedback loops. In addition to metabolic factors such as hypoxia, the process of angiogenesis is also regulated by hormonal changes such as increased estrogen, IGF-I, and TSH levels. By measuring microvascular density, differences in angiogenesis have been related to differences in tumor behavior, and similar techniques have been applied to both benign and malignant endocrine tumors with the aim of identification of tumors that subsequently behave in an aggressive fashion. In contrast to other tumor types, pituitary tumors are less vascular than normal pituitary tissue, although the mechanism for this observation is not known. A relationship between angiogenesis and tumor size, tumor invasiveness, and aggressiveness has been shown in some pituitary tumor types, but not in others. There are few reports on the role of microvascular density or angiogenic factors in adrenal tumors. The mechanism of the vascular tumors, which include adrenomedullary tumors, found in patients with Von Hippel Lindau disease has been well characterized, and clinical trials of antiangiogenic therapy are currently being performed in patients with Von Hippel Lindau disease. Thyroid tumors are more vascular than normal thyroid tissue, and there is a clear correlation between increased VEGF expression and more aggressive thyroid tumor behavior and metastasis. Although parathyroid tissue induces angiogenesis when autotransplanted and PTH regulates both VEGF and MMP expression, there are few studies of angiogenesis and angiogenic factors in parathyroid tumors. An understanding of the balance of angiogenesis in these vascular tumors and mechanisms of vascular control may assist in therapeutic decisions and allow appropriately targeted treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14570746     DOI: 10.1210/er.2002-0008

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  78 in total

1.  Vascularization of rat pituitary autografts.

Authors:  Matilde Lombardero; Andres Quintanar-Stephano; Sergio Vidal; Eva Horvath; Kalman Kovacs; Ricardo V Lloyd; Bernd W Scheithauer
Journal:  J Anat       Date:  2006-05       Impact factor: 2.610

2.  Angiogenesis in craniopharyngiomas: Microvascular density and tissue expression of the vascular endothelial growth factor (VEGF) and endostatin.

Authors:  Cristina M Dallago; Miriam C Oliveira; Ligia M Barbosa-Coutinho; Nelson P Ferreira
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 3.  Medical treatment of prolactinomas.

Authors:  Annamaria Colao; Silvia Savastano
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

4.  Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with pituitary adenomas.

Authors:  Anna Gruszka; Jolanta Kunert-Radek; Marek Pawlikowski; Henryk Stepien
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 5.  [Systemic therapy of malignant adrenal tumors].

Authors:  M Horstmann; A S Merseburger; A Stenzl; M Kuczyk
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

Review 6.  Paracrinicity: the story of 30 years of cellular pituitary crosstalk.

Authors:  C Denef
Journal:  J Neuroendocrinol       Date:  2008-01       Impact factor: 3.627

7.  Stimulating parathyroid cell proliferation and PTH release with phosphate in organ cultures obtained from patients with primary and secondary hyperparathyroidism for a prolonged period.

Authors:  Kishiko Nakajima; Ken-Ichi Umino; Yoshiaki Azuma; Seiichi Kosaka; Kazue Takano; Takao Obara; Kanji Sato
Journal:  J Bone Miner Metab       Date:  2009-02-06       Impact factor: 2.626

8.  VEGF and CD31 association in pituitary adenomas.

Authors:  Carolina Cristina; María Inés Perez-Millan; Guillermina Luque; Raúl Ariel Dulce; Gustavo Sevlever; Silvia Inés Berner; Damasia Becu-Villalobos
Journal:  Endocr Pathol       Date:  2010-09       Impact factor: 3.943

9.  Genetic interaction analysis of VEGF-A rs3025039 and VEGFR-2 rs2071559 identifies a genetic profile at higher risk to develop nodular goiter.

Authors:  A Molinaro; P Orlandi; F Niccolai; P Agretti; G De Marco; E Ferrarini; C Di Cosmo; P Vitti; P Piaggi; T Di Desidero; G Bocci; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2019-08-02       Impact factor: 4.256

Review 10.  Medical treatment of gastrinomas.

Authors:  Christoph J Auernhammer; Burkhard Göke
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.